FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olson, R. D.
Right arrow Articles by Mushlin, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, R. D.
Right arrow Articles by Mushlin, P. S.

The FASEB Journal, Vol 4, 3076-3086, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

RD Olson and PS Mushlin
Department of Medicine, University of Washington, Seattle 98195.

Anthracyclines, such as doxorubicin and daunorubicin, are highly effective anticancer agents that produce a well-described but incompletely understood cardiac toxicity. According to a popular hypothesis, anthracyclines injure the heart by generating oxygen- centered free radicals. This free radical hypothesis, however, appears to be inconsistent with many observations, such as the frequent failure of anthracyclines at cardiotoxic doses to produce evidence of increased free radical generation. Other explanations of cardiotoxicity involve platelet-activating factor, prostaglandins, histamine, calcium, and C- 13 hydroxy anthracycline metabolites. These C-13 hydroxy metabolites, on the basis of in vitro data, are considerably more potent than parent compounds as myocardial depressants and as inhibitors of ATPases of sarcoplasmic reticulum, mitochondria, and sarcolemma. Further studies will be required to determine whether metabolites or the other putative injurious agents discussed contribute substantially to the cardiomyopathy of anthracycline therapy. The hypotheses presented in this paper should provide a useful framework for subsequent investigations into the mechanisms of anthracycline cardiotoxicity.


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
N. Kassner, K. Huse, H.-J. Martin, U. Godtel-Armbrust, A. Metzger, I. Meineke, J. Brockmoller, K. Klein, U. M. Zanger, E. Maser, et al.
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Drug Metab. Dispos., October 1, 2008; 36(10): 2113 - 2120.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. H. Takahashi, O. S. Bains, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs
Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro
Drug Metab. Dispos., June 1, 2008; 36(6): 991 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Esaki, G. Takemura, K.-i. Kosai, T. Takahashi, S. Miyata, L. Li, K. Goto, R. Maruyama, H. Okada, H. Kanamori, et al.
Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1048 - H1057.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al.
Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
Pediatrics, February 1, 2008; 121(2): e387 - e396.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. L. Lyu, J. E. Kerrigan, C.-P. Lin, A. M. Azarova, Y.-C. Tsai, Y. Ban, and L. F. Liu
Topoisomerase II{beta} Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane
Cancer Res., September 15, 2007; 67(18): 8839 - 8846.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
N. Tang, G. Du, N. Wang, C. Liu, H. Hang, and W. Liang
Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin
J Natl Cancer Inst, July 4, 2007; 99(13): 1004 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
P. Venkatesh, B. Shantala, G. C. Jagetia, K. K. Rao, and M. S. Baliga
Modulation of Doxorubicin-Induced Genotoxicity by Aegle marmelos in Mouse Bone Marrow: A Micronucleus Study
Integr Cancer Ther, March 1, 2007; 6(1): 42 - 53.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
N. Kalay, E. Basar, I. Ozdogru, O. Er, Y. Cetinkaya, A. Dogan, T. Inanc, A. Oguzhan, N. K. Eryol, R. Topsakal, et al.
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2258 - 2262.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Jungsuwadee, M. P. Cole, R. Sultana, G. Joshi, J. Tangpong, D. A. Butterfield, D. K. St. Clair, and M. Vore
Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.
Mol. Cancer Ther., November 1, 2006; 5(11): 2851 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Salvatorelli, P. Menna, S. Cascegna, G. Liberi, A. M. Calafiore, L. Gianni, and G. Minotti
Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 424 - 433.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. C. Chua, X. Liu, J. Gao, R. C. Hamdy, and B. H. L. Chua
Multiple actions of pifithrin-{alpha} on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2606 - H2613.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-C. Lien, T. Noel, H. Liu, A. J. Stromberg, K.-C. Chen, and D. K. St. Clair
Phospholipase C-{delta}1 Is a Critical Target for Tumor Necrosis Factor Receptor-Mediated Protection against Adriamycin-Induced Cardiac Injury.
Cancer Res., April 15, 2006; 66(8): 4329 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Yi, R. Bekeredjian, N. J. DeFilippis, Z. Siddiquee, E. Fernandez, and R. V. Shohet
Transcriptional analysis of doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1098 - H1102.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y.-C. Lien, S.-M. Lin, R. Nithipongvanitch, T. D. Oberley, T. Noel, Q. Zhao, C. Daosukho, and D. K. St. Clair
Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection.
Mol. Cancer Ther., February 1, 2006; 5(2): 261 - 269.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. Li, G. Takemura, Y. Li, S. Miyata, M. Esaki, H. Okada, H. Kanamori, N. C. Khai, R. Maruyama, A. Ogino, et al.
Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy
Circulation, January 31, 2006; 113(4): 535 - 543.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. P. Cole, L. Chaiswing, T. D. Oberley, S. E. Edelmann, M. T. Piascik, S.-M. Lin, K. K. Kiningham, and D. K. St. Clair
The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity
Cardiovasc Res, January 1, 2006; 69(1): 186 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Tokarska-Schlattner, M. Zaugg, R. da Silva, E. Lucchinetti, M. C. Schaub, T. Wallimann, and U. Schlattner
Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H37 - H47.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer
The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE
Mol. Interv., June 1, 2005; 5(3): 163 - 171.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. W. Fisher, F. Salloum, A. Das, H. Hyder, and R. C. Kukreja
Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity
Circulation, April 5, 2005; 111(13): 1601 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. FOGLI, P. NIERI, and M. C. BRESCHI
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
FASEB J, April 1, 2004; 18(6): 664 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
E. Huettemann, T. Junker, K. P. Chatzinikolaou, G. Petrat, S. G. Sakka, L. Vogt, and K. Reinhart
The Influence of Anthracycline Therapy on Cardiac Function During Anesthesia
Anesth. Analg., April 1, 2004; 98(4): 941 - 947.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
E. Rock and A. DeMichele
Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors
J. Nutr., November 1, 2003; 133(11): 3785S - 3793.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Swift, J. McHowat, and N. Sarvazyan
Inhibition of Membrane-associated Calcium-independent Phospholipase A2 as a Potential Culprit of Anthracycline Cardiotoxicity
Cancer Res., September 15, 2003; 63(18): 5992 - 5998.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Kang and M. Weiss
Modeling the Metabolism of Idarubicin to Idarubicinol in Rat Heart: Effect of Rutin and Phenobarbital
Drug Metab. Dispos., April 1, 2003; 31(4): 462 - 468.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, S. Matoba, J. Asayama, S. Fushiki, H. Fliss, and M. Nakagawa
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
J. Am. Coll. Cardiol., March 5, 2003; 41(5): 870 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Liu, Z. Chen, C. C. Chua, Y.-S. Ma, G. A. Youngberg, R. Hamdy, and B. H. L. Chua
Melatonin as an effective protector against doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H254 - H263.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner
Multiple Interference of Anthracyclines with Mitochondrial Creatine Kinases: Preferential Damage of the Cardiac Isoenzyme and Its Implications for Drug Cardiotoxicity
Mol. Pharmacol., March 1, 2002; 61(3): 516 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
E Breitbart, L Lomnitski, A Nyska, Z Malik, M Bergman, Y Sofer, J K Haseman, and S Grossman
Effects of water-soluble antioxidant from spinach, NAO, on doxorubicin-induced heart injury
Human and Experimental Toxicology, July 1, 2001; 20(7): 337 - 345.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni
Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium
Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. McHowat, L. M. Swift, A. Arutunyan, and N. Sarvazyan
Clinical Concentrations of Doxorubicin Inhibit Activity of Myocardial Membrane-associated, Calcium-independent Phospholipase A2
Cancer Res., May 1, 2001; 61(10): 4024 - 4029.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. A. A. van Acker, E. Boven, K. Kramer, G. R. M. M. Haenen, A. Bast, and W. J. F. van der Vijgh
Frederine, a New and Promising Protector Against Doxorubicin-induced Cardiotoxicity
Clin. Cancer Res., May 1, 2001; 7(5): 1378 - 1384.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Zhou, A. Starkov, M. K. Froberg, R. L. Leino, and K. B. Wallace
Cumulative and Irreversible Cardiac Mitochondrial Dysfunction Induced by Doxorubicin
Cancer Res., January 1, 2001; 61(2): 771 - 777.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. A. Konorev, H. Zhang, J. Joseph, M. C. Kennedy, and B. Kalyanaraman
Bicarbonate exacerbates oxidative injury induced by antitumor antibiotic doxorubicin in cardiomyocytes
Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2424 - H2430.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann
Human Carbonyl Reductase Overexpression in the Heart Advances the Development of Doxorubicin-induced Cardiotoxicity in Transgenic Mice
Cancer Res., September 1, 2000; 60(18): 5158 - 5164.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. A. A. van Acker, S. A. B. E. van Acker, K. Kramer, G. R. M. M. Haenen, A. Bast, and W. J. F. van der Vijgh
7-Monohydroxyethylrutoside Protects against Chronic Doxorubicin-induced Cardiotoxicity When Administered Only Once Per Week
Clin. Cancer Res., April 1, 2000; 6(4): 1337 - 1341.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kimura, I. Fujita, N. Itoh, N. Muto, T. Nakanishi, K. Takahashi, J. Azuma, and K. Tanaka
Metallothionein Acts as a Cytoprotectant against Doxorubicin Toxicity
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 299 - 302.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
N. ANDRIEU-ABADIE, J.-P. JAFFRÉZOU, S. HATEM, G. LAURENT, T. LEVADE, and J.-J. MERCADIER
L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation
FASEB J, September 1, 1999; 13(12): 1501 - 1510.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
E. Delpy, S. N Hatem, N. Andrieu, C. de Vaumas, M. Henaff, C. Rucker-Martin, J.-P. Jaffrezou, G. Laurent, T. Levade, and J.-J. Mercadier
Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes
Cardiovasc Res, August 1, 1999; 43(2): 398 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. K Singal, N. Khaper, V. Palace, and D. Kumar
On the role of coenzyme Q10 in cardiovascular diseases
Cardiovasc Res, July 1, 1999; 43(1): 250 - 251.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. K. Working, M. S. Newman, T. Sullivan, and J. Yarrington
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1128 - 1133.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
D. B. Sawyer, R. Fukazawa, M. A. Arstall, and R. A. Kelly
Daunorubicin-Induced Apoptosis in Rat Cardiac Myocytes Is Inhibited by Dexrazoxane
Circ. Res., February 19, 1999; 84(3): 257 - 265.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
G. MINOTTI, G. CAIRO, and E. MONTI
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
FASEB J, February 1, 1999; 13(2): 199 - 212.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
P Venditti, M Balestrieri, T De Leo, and S Di Meo
Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres
Cardiovasc Res, June 1, 1998; 38(3): 695 - 702.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
G. Minotti, S. Recalcati, A. Mordente, G. Liberi, A. M. Calafiore, C. Mancuso, P. Preziosi, and G. Cairo
The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium
FASEB J, May 1, 1998; 12(7): 541 - 552.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
R. Olinski, P. Jaruga, M. Foksinski, K. Bialkowski, and J. Tujakowski
Epirubicin-Induced Oxidative DNA Damage and Evidence for Its Repair in Lymphocytes of Cancer Patients Who Are Undergoing Chemotherapy
Mol. Pharmacol., November 1, 1997; 52(5): 882 - 885.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
R. Jeyaseelan, C. Poizat, H.-Y. Wu, and L. Kedes
Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy. SELECTIVE SUPPRESSION OF REISKE IRON-SULFUR PROTEIN, ADP/ATP TRANSLOCASE, AND PHOSPHOFRUCTOKINASE GENES IS ASSOCIATED WITH ATP DEPLETION IN RAT CARDIOMYOCYTES
J. Biol. Chem., February 28, 1997; 272(9): 5828 - 5832.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. A. Sussman, S. F. Hamm-Alvarez, P. M. Vilalta, S. Welch, and L. Kedes
Involvement of Phosphorylation in Doxorubicin-Mediated Myofibril Degeneration: An Immunofluorescence Microscopy Analysis
Circ. Res., January 1, 1997; 80(1): 52 - 61.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
Y.-X. Wang and M. Korth
Effects of Doxorubicin on Excitation-Contraction Coupling in Guinea Pig Ventricular Myocardium
Circ. Res., April 1, 1995; 76(4): 645 - 653.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by The Federation of American Societies for Experimental Biology.